Sugi Predict

Sugi Predict / Compounds / SCHEMBL336340

SCHEMBL336340

SCHEMBL336340

Cc1ccc(S(=O)(=O)OCCC2CCCC2)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 3/20 0.44
▸ CYP3A4 P08684 1/20 0.44
▸ TSHR P16473 1/20 0.44
▸ ENPP3 O14638 2/20 0.42
▸ ENPP1 P22413 2/20 0.42
▸ ENPP2 Q13822 2/20 0.42
▸ CYP2D6 P10635 2/20 0.41
▸ CYP1A2 P05177 1/20 0.41
▸ ACHE P22303 1/20 0.41
▸ CA12 O43570 1/20 0.40
▸ CA1 P00915 1/20 0.40
▸ CA9 Q16790 1/20 0.40
▸ KMT2A Q03164 2/20 0.40
▸ MEN1 O00255 1/20 0.40
▸ POLB P06746 1/20 0.40
▸ SMN1; SMN2 Q16637 2/20 0.39
▸ CNR1 P21554 1/20 0.39
▸ CNR2 P34972 1/20 0.39
▸ STAT3 P40763 1/20 0.39
▸ LMNA P02545 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7026133 0.98 ALDH1A1 (0.46) ALDH1A1CYP3A4TSHRENPP3ENPP1
SCHEMBL334939 0.97 ACHE (0.44) ALDH1A1CYP3A4TSHRENPP3ENPP1
SCHEMBL244134 0.93 CYP2D6 (0.43) ALDH1A1CYP3A4TSHRCYP2D6CYP1A2
SCHEMBL23273024 0.91 CYP3A4 (0.42) ALDH1A1CYP3A4TSHRENPP3ENPP1
SCHEMBL3387501 0.89 ALDH1A1 (0.44) ALDH1A1CYP3A4TSHRENPP3ENPP1
SCHEMBL7028589 0.88 CYP3A4 (0.43) ALDH1A1CYP3A4TSHRENPP3ENPP1
SCHEMBL25642100 0.88 CYP3A4 (0.43) ALDH1A1CYP3A4TSHRENPP3ENPP1
SCHEMBL8541488 0.87 CYP3A4 (0.42) ALDH1A1CYP3A4TSHRENPP3ENPP1
SCHEMBL16104743 0.86 KMT2A (0.37) ALDH1A1CYP3A4TSHRENPP3ENPP1
SCHEMBL13068833 0.86 HTR6 (0.48) ALDH1A1CYP3A4CYP2D6CYP1A2CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4561585-A1 IP4-4,6 SUBSTITUTED DERIVATIVE COMPOUNDS FOR USE IN THE TREATMENT, INHIBITION OF PROGRESSION, AND PREVENTION OF ECTOPIC CALCIFICATION Sanifit Therapeutics S.A. (ES) 2025-06-04 — — EP disclosed
EP-4562019-A1 IP5 SUBSTITUTED COMPOUNDS Sanifit Therapeutics S.A. (ES) 2025-06-04 — — EP disclosed
CN-119855595-A IP4-4,6 substituted derivative compounds for treating ectopic calcification, inhibiting progression and preventing ectopic calcification 萨尼菲特治疗有限公司 2025-04-18 — — CN disclosed
CN-119630679-A IP5 substituted compounds 萨尼菲特治疗有限公司 2025-03-14 — — CN disclosed
US-20240109924-A1 IP4-4,6 SUBSTITUTED DERIVATIVE COMPOUNDS VIFOR (INTERNATIONAL) LTD. (CH) 2024-04-04 — — US disclosed
WO-2024023360-A1 IP5 SUBSTITUTED COMPOUNDS SANIFIT THERAPEUTICS, S.A. (ES) 2024-02-01 — — WO disclosed
WO-2024023359-A1 IP4-4,6 SUBSTITUTED DERIVATIVE COMPOUNDS FOR USE IN THE TREATMENT, INHIBITION OF PROGRESSION, AND PREVENTION OF ECTOPIC CALCIFICATION SANIFIT THERAPEUTICS, S.A. (ES) 2024-02-01 — — WO disclosed
EP-4284809-A1 IP4-4,6 SUBSTITUTED DERIVATIVE COMPOUNDS Sanifit Therapeutics S.A. (ES) 2023-12-06 — — EP disclosed
WO-2023213198-A1 USE OF AROMATIC FUSED RING COMPOUND AS TREK-1 ACTIVATOR, AND PHARMACEUTICAL COMPOSITION AND ANALGESIC CONTAINING SAME 华东师范大学 2023-11-09 — — WO disclosed
CN-117003756-A Use of aromatic condensed-cyclic compounds as TREK-1 activators, pharmaceutical compositions containing same, analgesics 华东师范大学 2023-11-07 — — CN disclosed
US-20080275032-A1 Pyridazinone compounds ANADYS PHARMACEUTICALS, INC. 2008-11-06 — — US disclosed
US-20080275032-A1 Pyridazinone compounds ANADYS PHARMACEUTICALS, INC. 2008-11-06 — — US disclosed
US-20080275032-A1 Pyridazinone compounds ANADYS PHARMACEUTICALS, INC. 2008-11-06 — — US disclosed
WO-2008082725-A1 PYRIDAZINONE COMPOUNDS ANADYS PHARMACEUTICALS, INC. (US) 2008-07-10 — — WO disclosed
WO-2008082725-A1 PYRIDAZINONE COMPOUNDS ANADYS PHARMACEUTICALS, INC. (US) 2008-07-10 — — WO disclosed
EP-0827498-B1 NEW ANTIVIRAL SUBSTITUTED PYRIMIDINEDIONE HOMOCARBOCYCLIC NUCLEOSIDE DERIVATIVES AND METHODS FOR THE PREPARATION THEREOF AND COMPOSITIONS CONTAINING THE SAME AS ACTIVE INGREDIENTS SAMJIN PHARM CO LTD (KR) 2003-06-18 — — EP disclosed
US-5922727-A 1-((SUBSTITUTED)CYCLOALK(EN)YLALKYL)-6-((SUB)PHENYL(CARBONYL, SULFIDE, OR OXO))-2,4-PYRIMIDINEDIONE DERIVATIVES HAVING SUPERIOR ANTIVIRAL ACTIVITIES; HIV SAMJIN PHARMACEUTICAL CO., LTD (KR) 1999-07-13 — — US disclosed
EP-0827498-A1 NEW ANTIVIRAL SUBSTITUTED PYRIMIDINEDIONE HOMOCARBOCYCLIC NUCLEOSIDE DERIVATIVES AND METHODS FOR THE PREPARATION THEREOF AND COMPOSITIONS CONTAINING THE SAME AS ACTIVE INGREDIENTS Samjin Pharmaceutical Co., Ltd. (KR) 1998-03-11 — — EP disclosed
WO-1997030979-A1 NEW ANTIVIRAL SUBSTITUTED PYRIMIDINEDIONE HOMOCARBOCYCLIC NUCLEOSIDE DERIVATIVES AND METHODS FOR THE PREPARATION THEREOF AND COMPOSITIONS CONTAINING THE SAME AS ACTIVE INGREDIENTS SAMJIN PHARMACEUTICAL CO., LTD. (KR) 1997-08-28 — — WO disclosed
EP-0265247-A1 Cyclopentyl ethers and their preparation and pharmaceutical formulation GLAXO GROUP LIMITED (GB) 1988-04-27 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240109924-A1 IP4-4,6 SUBSTITUTED DERIVATIVE COMPOUNDS IPO4, TPX2, IPO9 ALDH1A1 4700/4885CYP3A4 372/4885TSHR 358/4885
US-20080275032-A1 Pyridazinone compounds HAVCR2, PLPBP, CYP3A43 ALDH1A1 1191/4885CYP3A4 11/4885TSHR 3163/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.